Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms

• Status: Enrolling by invitation
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gundersen Lutheran Medical Foundation
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• Patients between the ages of 18 and 70 years old.

• Planning to undergo ureteroscopy with ureteral stent placement at our site.

• Able to read and understand an English language survey (USSQ).

Exclusion Criteria:

1. Patients who are unable to provide informed consent.

2. Patients who are already taking an alpha-blocker.

3. Patients with hypersensitivity or known adverse side effects of tamsulosin or its ingredients and those who are not candidates for tamsulosin per attending Urologist discretion.

4. Patients with a preexisting bladder condition including UTI within 30 days of the procedure.

5. Patients with hepatitis C on boceprevir.

6. Patients who have medical conditions known to be associated with chronic pain, those taking medications for chronic pain such as gabapentin or a chronic opioid per the judgement of the PI, or those with a pain contract on file.

7. Women who are pregnant or planning to become pregnant.